title: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
abstract: Tamoxifen significantly reduces tumor recurrence in certain patients with early-stage estrogen receptor-positive breast cancer, but markers predictive of treatment failure have not been identified. Here, we generated gene expression profiles of hormone receptor-positive primary breast cancers in a set of 60 patients treated with adjuvant tamoxifen monotherapy. An expression signature predictive of disease-free survival was reduced to a two-gene ratio, HOXB13 versus IL17BR, which outperformed existing biomarkers. Ectopic expression of HOXB13 in MCF10A breast epithelial cells enhances motility and invasion in vitro, and its expression is increased in both preinvasive and invasive primary breast cancer. The HOXB13:IL17BR expression ratio may be useful for identifying patients appropriate for alternative therapeutic regimens in early-stage breast cancer.
authors.affiliation: Arcturus Bioscience, Inc., 2715 Loker Avenue West, Carlsbad, CA 92008, USA.
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Ma
authors.forename: Zuncai
authors.initials: Z
authors.lastname: Wang
authors.forename: Paula D
authors.initials: PD
authors.lastname: Ryan
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Isakoff
authors.forename: Anne
authors.initials: A
authors.lastname: Barmettler
authors.forename: Andrew
authors.initials: A
authors.lastname: Fuller
authors.forename: Beth
authors.initials: B
authors.lastname: Muir
authors.forename: Gayatry
authors.initials: G
authors.lastname: Mohapatra
authors.forename: Ranelle
authors.initials: R
authors.lastname: Salunga
authors.forename: J Todd
authors.initials: JT
authors.lastname: Tuggle
authors.forename: Yen
authors.initials: Y
authors.lastname: Tran
authors.forename: Diem
authors.initials: D
authors.lastname: Tran
authors.forename: Ana
authors.initials: A
authors.lastname: Tassin
authors.forename: Paul
authors.initials: P
authors.lastname: Amon
authors.forename: Wilson
authors.initials: W
authors.lastname: Wang
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Edward
authors.initials: E
authors.lastname: Enright
authors.forename: Kimberly
authors.initials: K
authors.lastname: Stecker
authors.forename: Eden
authors.initials: E
authors.lastname: Estepa-Sabal
authors.forename: Barbara
authors.initials: B
authors.lastname: Smith
authors.forename: Jerry
authors.initials: J
authors.lastname: Younger
authors.forename: Ulysses
authors.initials: U
authors.lastname: Balis
authors.forename: James
authors.initials: J
authors.lastname: Michaelson
authors.forename: Atul
authors.initials: A
authors.lastname: Bhan
authors.forename: Karleen
authors.initials: K
authors.lastname: Habin
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Baer
authors.forename: Joan
authors.initials: J
authors.lastname: Brugge
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Haber
authors.forename: Mark G
authors.initials: MG
authors.lastname: Erlander
authors.forename: Dennis C
authors.initials: DC
authors.lastname: Sgroi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D045744:Cell Line, Tumor; D002465:Cell Movement; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D018398:Homeodomain Proteins / Q000096:biosynthesis / Q000235:genetics*; D006801:Humans; D017403:In Situ Hybridization; D020381:Interleukin-17 / Q000096:biosynthesis / Q000235:genetics*; D016015:Logistic Models; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011379:Prognosis; D012372:ROC Curve; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; C484414:HOXB13 protein, human; D018398:Homeodomain Proteins; D020381:Interleukin-17; D013629:Tamoxifen